S Y Lei,R S Zheng,W Q Chen
S Y Lei
Objective: To analyze the incidence of malignant tumors in children and adolescents (aged 0-19 years) in China in 2022. Methods: Data were sourced from GLOBOCAN 2022 and Cancer Incidence in Five Continents (CI5) Volume Ⅻ. Incidence data by...
[Chinese expert consensus on NGS-based probe design for tumor comprehensive genomic profiling testing (2026 edition)] [0.03%]
中国肿瘤全面基因组检测NGS定制探针设计专家共识（2026版）
Tumor Pathology Committee of China Anti-Cancer Association
Tumor Pathology Committee of China Anti-Cancer Association
Comprehensive genomic profiling (CGP) based on next-generation sequencing (NGS) has emerged as a mainstream approach for clinical diagnosis and treatment with the development of precision oncology. However, as the first stage of NGS testing...
[Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2025 edition)] [0.03%]
《非肌层浸润性膀胱癌腔内治疗专家共识（2025版）》
Urological Chinese Oncology Group
Urological Chinese Oncology Group
Bladder cancer is one of the common malignant tumors. In 2022, China is estimated to have approximately 92,900 new cases of bladder cancer, including about 73,200 cases in males and 19,700 cases in females. It is projected that around 41,40...
[Expert consensus on the clinical application of PARP inhibitors in breast cancer (2025 edition)] [0.03%]
中国乳腺癌PARP抑制剂临床应用专家共识(2025年版)
Professional Committee on Clinical Research of Oncology Drugs, China Anti-Cancer Association;Expert Committee for Monitoring the Clinical Application of Antitumor Drugs;Breast Cancer Expert Committee of Nati
Professional Committee on Clinical Research of Oncology Drugs
Breast cancer poses a major threat to women's health in China, with its incidence rate continuously rising, leading to an increasing disease burden and an urgent need for novel and effective treatment strategies. In recent years, poly ADP-r...
[Expert consensus on the diagnosis and treatment of non-Hodgkin lymphoma in children and adolescents (2026 edition)] [0.03%]
中国儿童及青少年非霍奇金淋巴瘤诊断与治疗专家共识（2026版）
Lymphoma Group, Oncology Branch, Chinese Medical Association
Lymphoma Group
Non-Hodgkin lymphoma (NHL) is a common malignant tumor in children, accounting for approximately 7% of all childhood malignancies, with a higher incidence rate among adolescents. After standardized treatment, the overall survival rate excee...
Y Fang,H Y Huang,D W Wu et al.
Y Fang et al.
Objective: To systematically summarize the research progress of clinical trials on breast cancer drugs in China from 2011 to 2022, as well as provide an overview of the marketed drugs. The goal is to offer data and decision-making evidence ...
[The value of fine-needle aspiration biopsy wash-out fluid in the detection for medullary thyroid carcinoma] [0.03%]
细针抽吸灌洗液检测甲状腺髓样癌的价值研究
J Zhao,L H Zhao,Y Deng et al.
J Zhao et al.
Objective: To investigate the preoperative diagnostic value of ultrasound-guided fine-needle aspiration biopsy wash-out fluid (FNA-CT) in medullary thyroid carcinoma (MTC) with mildly elevated serum calcitonin levels. Methods: 267 patients ...
[Glutathione-responsive AP site captor Probe-NEt for anaplastic thyroid cancer: in vitro and in vivo experimental studies] [0.03%]
基于γ-谷氨酰胺硫辛酸酯的AP位点捕获探针PROTEN在甲状腺未分化癌中的应用研究体外及体内实验研究报告
M X Su,J Y Chai,R G Zhang et al.
M X Su et al.
Objective: To exploit the elevated glutathione (GSH) levels in the tumor microenvironment and investigate the therapeutic efficacy of a novel glutathione-responsive apurinic/apyrimidinic (AP) site captor, Probe-NEt, against anaplastic thyro...
[Omics analysis of the regulatory role of APOBEC in the immune microenvironment of head and neck squamous cell carcinoma with different HPV status] [0.03%]
APOBEC在不同HPV状态的头颈部鳞癌免疫微环境中的调控作用的组学分析
Y G Xu,D X Li,C Wu
Y G Xu
Objective: To investigate the differences in apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) between human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinoma (HNSCC) patients, anal...
[Cancer incidence and mortality across diverse geographical regions in China, 2024] [0.03%]
[2024年中国不同地理区域的癌症发病率和死亡率]
K X Sun,L Li,S M Wang et al.
K X Sun et al.
Objective: The National Central Cancer Registry estimates the cancer diseases burden in China in 2024. Methods: We incorporated the surveillance data from 919 cancer registries of year 2019 and the longitudinal surveillance data from 106 re...